Provider diagnosis documentation: Updates to Medicare Risk Adjustment/HCC

Nov. 2023Important Notices
Please join UPMC Health Plan’s Risk Adjustment/HCC Coding Education Program Director Marlana Tice for a live, CME-accredited webinar on Wednesday, Jan. 24, from noon to 1 p.m., that will provide an overview on provider diagnosis code documentation. During this presentation, viewers will learn:

  • An understanding of diagnosis documentation and ICD-10-CM coding importance for Medicare Advantage patients.
  • Examples of best practice documentation for diagnoses as it relates to notable CMS changes and updates to many ICD-10-CM codes/HCC in the new Medicare Advantage risk adjustment model.
  • Ways to improve diagnosing, documenting, and reporting codes with better specificity based on ICD-10-CM classification.

Presenter:
Marlana R. Tice, BA, CCS-P, CPC, CCS, AHIMA-Approved ICD-10-CM/PCS Trainer, Program Director, Risk Adjustment-HCC Coding Education, UPMC Health Plan

Register now. This webinar will be recorded.

Certified coders may earn 1.0 CEU from the American Academy of Professional Coders (AAPC).

You may earn continuing medical education (CME) credits for attending this webinar. This activity is approved for AMA PRA Category 1 Credit™ and ANCC. Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Provider is responsible for verifying CME eligibility.

Recent Announcements

Voluntary nationwide recall: Atorvastatin (Alkem – October)

Ascend Laboratories LLC is recalling multiple lots of Atorvastatin Calcium Tablets USP. Atorvastatin is used for the treatment of high cholesterol and to reduce the risk of certain cardiovascular events, such as heart attack and stroke.
Nov. 2025Pharmacy Updates

October 2025 UPMC for You and UPMC Community HealthChoices formulary update

Effective Oct. 1, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to nonparticipation in the Medicaid Drug Rebate Program.
Oct. 2025Pharmacy Updates

Voluntary nationwide recall: Ocaliva (Intercept – September)

Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).
Oct. 2025Pharmacy Updates